Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 4 Scintigraphic and positron emission computed tomographic (PET) findings (Case 2). Nuclear cardiographic evaluations showed marked perfusion (Tc-99m sestamibi [MIBI]) metabolic (I-123 beta-methyl-p-iodophenyl pentadecanoic acid [BMIPP] or I-123 metaiodobenzyl-guanitidine [MIBG]) mismatches mainly at the left ventricular apex. However, in the subacute period, this perfusion metabolic mismatch decreased after the functional recovery (three-dimensional left ventriculography by Tc-99m MIBI). After five months, PET by N-13 ammonia showed improvement in the coronary flow reserve (CFR) assessed by dipyridamole administration. EDV = end-diastolic volume; EF = ejection fraction; ESV = end-systolic volume; MBF = myocardial blood flow; SPECT = single photon emission computed tomography.
|
